Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
Optical resolution method of lenalidomide
US10047068B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10047068-B2 |
| Application number | US-201515312788-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 21, 2015 |
| Priority date | May 22, 2014 |
| Publication date | Aug 14, 2018 |
| Grant date | Aug 14, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for separating and purifying lenalidomide enantiomers, wherein an enantiomeric mixture of lenalidomide is supplied to chromatography, and an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols and mixtures thereof is used as the mobile phase for optical resolution of each enantiomer of lenalidomide from a racemic mixture of lenalidomide, wherein the aprotic solvent is ethyl acetate, acetonitrile, or a combination thereof. 2. The method according to claim 1 , wherein the enantiomer of lenalidomide is the S-form. 3. The method according to claim 1 , wherein the enantiomer of lenalidomide is the R-form. 4. The method according to claim 1 , wherein in the optical resolution, the S-form of lenalidomide elutes earlier than the R-form of lenalidomide. 5. The method according to claim 1 , wherein the secondary alcohol is isopropanol. 6. The method according to claim 1 , wherein a column is used having a polysaccharide derivative as the stationary phase. 7. The method according to claim 6 , wherein the column is Chiralpak™ IA or Chiralpak™ IC.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
Specific type of solvent · CPC title
Chiral chromatography · CPC title
- C07D401/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10047068B2 cover?
- The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.
- Who is the assignee on this patent?
- Shiseido Co Ltd, Shiseido Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).